Why Genetic Testing Matters for Neurological Conditions

Neurological conditions — disorders of the brain, spinal cord, and nervous system — affect hundreds of millions of people worldwide and represent some of the most complex diagnostic challenges in medicine. Genetics plays a central role in many neurological conditions, from rare single-gene disorders to common conditions like Alzheimer's disease and Parkinson's disease. Understanding the genetic basis of neurological conditions is transforming diagnosis, treatment, and prevention.

The Genetic Landscape of Neurological Conditions

Rare Monogenic Neurological Disorders

Many rare neurological conditions are caused by mutations in single genes. These include Huntington's disease (HTT gene), spinal muscular atrophy (SMN1 gene), Duchenne muscular dystrophy (DMD gene), Friedreich's ataxia (FXN gene), and Wilson's disease (ATP7B gene). For these conditions, genetic testing provides definitive diagnosis, enables family counselling, and increasingly guides targeted treatment.

Common Neurological Conditions with Genetic Components

• Alzheimer's disease: APOE4 is the strongest genetic risk factor for late-onset Alzheimer's. Rare mutations in APP, PSEN1, and PSEN2 cause early-onset familial Alzheimer's.
• Parkinson's disease: Mutations in LRRK2, SNCA, PINK1, and PRKN are associated with familial Parkinson's. GBA variants increase risk of both Parkinson's and Lewy body dementia.
• Epilepsy: Approximately 30–40% of epilepsy has a clear genetic basis, with hundreds of epilepsy-associated genes identified.
• Multiple sclerosis: HLA-DRB1*15:01 is the strongest genetic risk factor. Multiple other variants contribute to polygenic risk.
• Migraine: Strong genetic component; CACNA1A mutations cause familial hemiplegic migraine.

Why Genetic Diagnosis Matters

Precision Treatment

For many genetic neurological conditions, the specific mutation determines the optimal treatment. Spinal muscular atrophy caused by SMN1 deletion responds to nusinersen, risdiplam, and onasemnogene abeparvovec — gene therapies that have transformed outcomes for affected children. Dravet syndrome caused by SCN1A mutations requires avoidance of sodium channel blockers that worsen seizures.

Pharmacogenomics

Genetic variants in drug-metabolizing enzymes (CYP2D6, CYP2C19) affect how neurological medications are processed — influencing efficacy and side effect risk for antidepressants, antipsychotics, antiepileptics, and pain medications.

Family Counselling and Cascade Testing

Identifying a genetic cause in one family member enables targeted testing of relatives — identifying those at risk before symptoms appear and enabling preventive monitoring and intervention.

FAQs

Should I get genetic testing if I have a family history of Alzheimer's?

APOE genotyping can identify elevated risk for late-onset Alzheimer's, but it's not deterministic — APOE4 increases risk but doesn't guarantee disease. Testing for early-onset familial Alzheimer's mutations (APP, PSEN1, PSEN2) is more clinically actionable. Genetic counselling before and after testing is strongly recommended.

What genetic tests are available for neurological conditions in India?

Options include targeted gene panels for specific conditions, whole exome sequencing (WES) for undiagnosed neurological conditions, and pharmacogenomic testing for medication optimization. MapmyGenome offers several of these options backed by NABL-certified labs.